Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2015 | Pages:
65 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Deep Vein Thrombosis (DVT) - Pipeline Review, H2 2015 Summary Global Markets Direct's, 'Deep Vein Thrombosis (DVT) - Pipeline Review, H2 2015', provides an overview of the Deep Vein Thrombosis (DVT)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Deep Vein Thrombosis (DVT), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Deep Vein Thrombosis (DVT) and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Deep Vein Thrombosis (DVT) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Deep Vein Thrombosis (DVT) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Deep Vein Thrombosis (DVT) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Deep Vein Thrombosis (DVT) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Deep Vein Thrombosis (DVT) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Deep Vein Thrombosis (DVT) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Deep Vein Thrombosis (DVT) Overview 7 Therapeutics Development 8 Pipeline Products for Deep Vein Thrombosis (DVT) - Overview 8 Pipeline Products for Deep Vein Thrombosis (DVT) - Comparative Analysis 9 Deep Vein Thrombosis (DVT) - Therapeutics under Development by Companies 10 Deep Vein Thrombosis (DVT) - Therapeutics under Investigation by Universities/Institutes 11 Deep Vein Thrombosis (DVT) - Pipeline Products Glance 12 Late Stage Products 12 Clinical Stage Products 13 Early Stage Products 14 Deep Vein Thrombosis (DVT) - Products under Development by Companies 15 Deep Vein Thrombosis (DVT) - Products under Investigation by Universities/Institutes 16 Deep Vein Thrombosis (DVT) - Companies Involved in Therapeutics Development 17 3SBio Inc. 17 Archemix Corp. 18 Bristol-Myers Squibb Company 19 F. Hoffmann-La Roche Ltd. 20 Generex Biotechnology Corporation 21 Laboratorios Farmaceuticos Rovi, S.A. 22 Merrion Pharmaceuticals Plc 23 Deep Vein Thrombosis (DVT) - Therapeutics Assessment 24 Assessment by Monotherapy Products 24 Assessment by Target 25 Assessment by Mechanism of Action 27 Assessment by Route of Administration 29 Assessment by Molecule Type 31 Drug Profiles 33 Antisense RNAi Oligonucleotide for DVT - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 apixaban - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 ARC-15105 - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 enoxaparin biosimilar - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 fondaparinux sodium - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 fondaparinux sodium - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 Polysaccharide to Inhibit Factor X for Deep Vein Thrombosis - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 Small Molecules for Hematological Disorders and Cancer - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 TRX-1 - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 Deep Vein Thrombosis (DVT) - Recent Pipeline Updates 43 Deep Vein Thrombosis (DVT) - Dormant Projects 50 Deep Vein Thrombosis (DVT) - Discontinued Products 51 Deep Vein Thrombosis (DVT) - Product Development Milestones 52 Featured News & Press Releases 52 Nov 30, 2015: New Data from Bayer's Portfolio in Thrombosis to be Presented at ASH 2015 52 Nov 06, 2015: Important Global Data from XARELTO EXPLORER Cardiovascular Research Program Highlighted in 17 Presentations at the American Heart Association Scientific Sessions 2015 52 Nov 05, 2015: Janssen to Present Posters on rivaroxaban at the 2015 American Society of Hematology Annual Meeting 55 May 04, 2015: Bayer's Xarelto Approved in China for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation and for the Treatment of Deep Vein Thrombosis 55 Apr 07, 2015: Xarelto Litigation Update: Legal-Bay Lawsuit Settlement Funding Reports Issuance of New Court Documents 56 Mar 30, 2015: New Study Shows Reduced Hospital Admissions and Costs for Deep Vein Thrombosis Patients Treated with XARELTO Compared to Traditional Therapy, With No Difference in Subsequent Hospital Visits 57 Mar 02, 2015: Findings to be Presented at Annual Scientific Session of the American College of Cardiology About an Additional Potential Reversal Strategy for and Real-World Safety Performance of XARELTO 58 Nov 26, 2014: ELIQUIS approved for treatment of venous thromboembolic events (Deep Vein Thrombosis [DVT], Pulmonary Embolism [PE]) and prevention of recurrent DVT and PE 59 Aug 22, 2014: U.S. FDA Approves Eliquis for the Treatment of Deep Vein Thrombosis and Pulmonary Embolism, and for the Reduction in the Risk of Recurrent DVT and PE Following Initial Therapy 60 Jul 29, 2014: European Commission Approves Eliquis (apixaban) for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Prevention of Recurrent DVT and PE 62 Appendix 64 Methodology 64 Coverage 64 Secondary Research 64 Primary Research 64 Expert Panel Validation 64 Contact Us 64 Disclaimer 65
List of Tables
Number of Products under Development for Deep Vein Thrombosis (DVT), H2 2015 8 Number of Products under Development for Deep Vein Thrombosis (DVT) - Comparative Analysis, H2 2015 9 Number of Products under Development by Companies, H2 2015 10 Number of Products under Investigation by Universities/Institutes, H2 2015 11 Comparative Analysis by Late Stage Development, H2 2015 12 Comparative Analysis by Clinical Stage Development, H2 2015 13 Comparative Analysis by Early Stage Development, H2 2015 14 Products under Development by Companies, H2 2015 15 Products under Investigation by Universities/Institutes, H2 2015 16 Deep Vein Thrombosis (DVT) - Pipeline by 3SBio Inc., H2 2015 17 Deep Vein Thrombosis (DVT) - Pipeline by Archemix Corp., H2 2015 18 Deep Vein Thrombosis (DVT) - Pipeline by Bristol-Myers Squibb Company, H2 2015 19 Deep Vein Thrombosis (DVT) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 20 Deep Vein Thrombosis (DVT) - Pipeline by Generex Biotechnology Corporation, H2 2015 21 Deep Vein Thrombosis (DVT) - Pipeline by Laboratorios Farmaceuticos Rovi, S.A., H2 2015 22 Deep Vein Thrombosis (DVT) - Pipeline by Merrion Pharmaceuticals Plc, H2 2015 23 Assessment by Monotherapy Products, H2 2015 24 Number of Products by Stage and Target, H2 2015 26 Number of Products by Stage and Mechanism of Action, H2 2015 28 Number of Products by Stage and Route of Administration, H2 2015 30 Number of Products by Stage and Molecule Type, H2 2015 32 Deep Vein Thrombosis (DVT) Therapeutics - Recent Pipeline Updates, H2 2015 43 Deep Vein Thrombosis (DVT) - Dormant Projects, H2 2015 50 Deep Vein Thrombosis (DVT) - Discontinued Products, H2 2015 51
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
